E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Randomized trials of magnesium in acute myocardial infarction: big numbers do not tell the whole story.
Journal ArticleDOI
Dynamic TIMI Risk Score for STEMI
Sameer Amin,David A. Morrow,Eugene Braunwald,Sarah Sloan,Charles F. Contant,Sabina A. Murphy,Elliott M. Antman +6 more
TL;DR: This score is a prospectively derived, validated means of estimating 1‐year mortality of STEMI at hospital discharge and can serve as a clinically useful tool by incorporating events during the index hospitalization.
Journal ArticleDOI
Pooling Data From Individual Clinical Trials in the COVID-19 Era.
TL;DR: This Viewpoint proposes principles and processes to allow pooling of individual patient data from clinical trials given decelerating participant recruitment at sites where the COVID-19 surge has been controlled and new cases are diminishing.
Journal ArticleDOI
Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial
Robert P. Giugliano,Christian T. Ruff,Stephen D. Wiviott,Francesco Nordio,Sabina A. Murphy,Johannes A.N. Kappelhof,Minggao Shi,Michele Mercuri,Elliott M. Antman,Eugene Braunwald +9 more
TL;DR: Fewer total and cardiovascular deaths were observed with edoxaban as compared with warfarin in the ENGAGE AF-TIMI 48 trial, and this predominantly resulted from the significantly lower rate of major bleeding with Edoxaban.
Journal ArticleDOI
Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial
David A. Morrow,Sabina A. Murphy,Carolyn H. McCabe,Nigel Mackman,Hing C. Wong,Elliott M. Antman +5 more
TL;DR: It is postulate that the mucosal bleeding observed with this potent inhibitor of thrombin generation may reflect antiplatelet effects resulting from networking between the coagulation cascade and platelet pathways that could prove clinically relevant with this novel class of anticoagulant effects.